Physician profile
Thomas J Capasso
NPI 1245643873
$1,807.43
in general payments reported to CMS, 2019-2025
15 companies · $985 in 2025
The $985 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.89 · 2020: $165 · 2021: $181 · 2022: $177 · 2023: $82.24 · 2024: $198 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $715 · Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $714.68 |
| Food and Beverage | $551.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,032.47 | 2024-2025 | |
| Smith+Nephew, INC. | $230.73 | 2022-2024 | Oasis, Versajet, Collagenase Santyl |
| Zimmer Biomet Holdings, INC. | $141.22 | 2021 | |
| Haemonetics Corporation | $110.17 | 2020 | |
| Kci USA, INC. | $62.17 | 2020-2023 | Promogran Prisma |
| Polynovo North America LLC | $50.83 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $27.44 | 2022-2023 | Andexxa |
| Aroa Biosurgery Incorporated | $26.77 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.35 | 2023 | Gattex |
| Shionogi INC | $18.29 | 2023 | Fetroja |
| Acell, INC. | $18.09 | 2020 | |
| Z-Medica, LLC | $16.59 | 2020 | |
| Merck Sharp & Dohme LLC | $13.65 | 2022 | |
| Depuy Synthes Sales INC. | $12.96 | 2022 | |
| Kerecis Limited | $7.81 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Capasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.